#United States #Henderson #VolitionRx #Lateral Flow #Missionpharma

VolitionRx Collaborates with Missionpharma for Global Health Impact

VolitionRx Limited, a multinational leader in epigenetics, has taken a significant step forward by signing a non-binding Letter of Intent (LOI) with Missionpharma, a reputed Danish company specializing in healthcare solutions. This partnership is poised to transform the landscape of NETosis diagnostics through the development of Volition's innovative Lateral Flow Technology (LFT).

A Game-Changing Partnership

On October 27, 2026, VolitionRx announced the agreement which aims to leverage its prototype LFT for NETosis in achieving better health outcomes globally. This technology is particularly important as it potentially allows for rapid and decentralized testing, which can be crucial in resource-limited settings.

Dr. Gaetan Michel, Chief Operating Officer at Volition, emphasized the importance of this partnership, saying, "Our latest results show that this finger prick test could be accessible worldwide, especially in high-need areas. This has the potential to improve early detection of diseases linked to NETosis, such as sepsis, which affects millions annually."

The Nu.Q® NETs test developed by Volition quantifies circulating nucleosomes and neutrophil extracellular traps as early indicators of hyper-inflammation. The partnership's goal extends beyond just the diagnostic phase; it aims to roll out this technology in various healthcare settings, prioritizing lower-income regions where diagnostic challenges are more pronounced.

Addressing an Urgent Health Issue

Agustin Travaini from Missionpharma stated, "We intend to work closely with Volition to explore ways to introduce and scale their cutting-edge test for NETosis. This collaboration may lead to affordable manufacturing and distribution opportunities, especially in low- and middle-income countries (LMICs)."

Statistics illustrate the global health emergency at hand: an estimated 2.3 million newborns die each year from sepsis-related complications, particularly in African nations where healthcare resources are limited. The innovative use of Volition's tests in a targeted way can potentially save countless lives, underscoring the critical nature of this partnership.

Optimizing Global Health Outcomes

In the words of Dr. Andrew Retter, a medical consultant for Volition, the introduction of the LFT could revolutionize diagnosis and treatment protocols for neonatal sepsis. "We are focusing on defining a specific use case for this tool to ensure it effectively serves the needs of vulnerable populations."

The collaboration signifies more than just a development project; it is a commitment to enhancing healthcare accessibility and effectiveness in regions where the stakes couldn't be higher. By decentralizing testing, both companies aim to significantly broaden their market and ultimately save lives.

The Way Forward

This partnership has robust backing from major health agencies, including those under the United Nations, ensuring that the efforts are aligned with global health priorities. With an estimated 80% of sepsis-related deaths in newborns being preventable through early diagnosis, the stakes are substantial.

The first phase of this collaboration will likely focus on the establishment and evaluation of the LFT in clinical settings, paving the way for future innovations in disease management and treatment. As VolitionRx and Missionpharma move forward, the world is watching closely, hopeful for breakthroughs in fighting sepsis and related diseases.

In conclusion, the LOI between VolitionRx and Missionpharma is a promising development that may lead to transformative changes in global health diagnostics, particularly for vulnerable populations. Their combined expertise has the potential to increase access to essential healthcare solutions and save lives.